These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9559779)

  • 1. Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.
    Walker S; Tailor SA; Lee M; Louie L; Louie M; Simor AE
    Antimicrob Agents Chemother; 1998 Apr; 42(4):762-6. PubMed ID: 9559779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
    Kretschmar M; Nichterlein T; Hannak D; Hof H
    Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
    Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Getting the Jump on the Development of Bullfrog Oil Microemulsions: a Nanocarrier for Amphotericin B Intended for Antifungal Treatment.
    Oliveira WN; Amaral-Machado L; Alencar EN; Marcelino HR; Genre J; Silva-Rocha WP; Gondim AD; Chaves GM; Fernandes-Pedrosa MF; Egito EST
    AAPS PharmSciTech; 2018 Aug; 19(6):2585-2597. PubMed ID: 29916194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines in mice treated with amphotericin B-intralipid.
    Shadkchan Y; Keisari Y; Segal E
    Med Mycol; 2004 Apr; 42(2):123-8. PubMed ID: 15124865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?
    Swenson CE; Perkins WR; Roberts P; Ahmad I; Stevens R; Stevens DA; Janoff AS
    Antimicrob Agents Chemother; 1998 Apr; 42(4):767-71. PubMed ID: 9559780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice.
    Shadkchan Y; Segal E
    J Antimicrob Chemother; 1999 Dec; 44(6):787-90. PubMed ID: 10590279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of antifungal and cytotoxic activities as also the therapeutic safety of the oxidized form of amphotericin B.
    Klimek K; Strubińska J; Czernel G; Ginalska G; Gagoś M
    Chem Biol Interact; 2016 Aug; 256():47-54. PubMed ID: 27350166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations.
    Welte R; Eschertzhuber S; Weiler S; Leitner-Rupprich S; Aigner M; Lass-Flörl C; Stienecke E; Bellmann-Weiler R; Joannidis M; Bellmann R
    Int J Antimicrob Agents; 2015 Sep; 46(3):325-31. PubMed ID: 26119497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest.
    Lovero G; Giglio O; Rutigliano S; Diella G; Caggiano G; Montagna MT
    J Med Microbiol; 2017 Mar; 66(2):213-216. PubMed ID: 27959780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains].
    Yalçin B; Kalkanci A; Gürelik F; Fidan I; Kustimur S; Ozdek S
    Mikrobiyol Bul; 2010 Jan; 44(1):65-70. PubMed ID: 20455400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].
    Chavanet P; Charlier N; Brenet A; Goux A; Muggéo E; Caillot D; Casasnovas O; Kistermann JP; Waldner A; Portier H
    Pathol Biol (Paris); 1992 May; 40(5):507-12. PubMed ID: 1495835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
    Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
    Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
    J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
    Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
    Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B.
    Ludwig DB; de Camargo LEA; Khalil NM; Auler ME; Mainardes RM
    Mycopathologia; 2018 Aug; 183(4):659-668. PubMed ID: 29497926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii.
    Batista-Duharte A; Lastre M; Romeu B; Portuondo DL; Téllez-Martínez D; Manente FA; Pérez O; Carlos IZ
    Int Immunopharmacol; 2016 Nov; 40():277-287. PubMed ID: 27639705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice.
    Shadkchan Y; Segal E
    J Antimicrob Chemother; 2001 Aug; 48(2):245-51. PubMed ID: 11481296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
    J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.